The Evolving Landscape of Newly Diagnosed Multiple Myeloma

Now Viewing

EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma

EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM

EP: 3.Advances in the Treatment of High-Risk MM

EP: 4.Role of Transplant and MRD in Newly Diagnosed MM

EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM

EP: 6.Treatment of Multiple Myeloma at Early Relapse

EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse

EP: 8.Updates on BCMA-Targeting Bispecifics in MM

EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma

EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma

EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma

This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.

Patel provides an overview of recent developments in treating newly diagnosed multiple myeloma patients. The distinction between transplant-eligible vs ineligible is blurring, with some fit patients choosing to defer transplant. Triplet regimens have shifted to quadruplet regimens incorporating anti-CD38 monoclonal antibodies like daratumumab or isatuximab. Studies like GRIFFIN and PERSEUS show quadruplet regimens improve responses over triplets for both standard-risk and high-risk transplant-eligible patients.

For transplant-ineligible/frail patients, lenalidomide-bortezomib-dexamethasone (RVd) remains an option, but daratumumab-lenalidomide-dexamethasone (DRd) based on the MAIA trial may provide an even longer treatment-free interval. For high-risk transplant-ineligible patients, a quadruplet approach with RVd plus daratumumab is also being studied.

A key goal of therapy has become attaining minimal residual disease (MRD) negativity, which is associated with improved progression-free and overall survival. The depth of response seen with quadruplet regimens may help support regulatory approval of MRD as a biomarker for novel agents.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.